HC Wainwright Reiterates “Sell” Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating restated by equities researchers at HC Wainwright in a research note issued on Wednesday,Benzinga reports.

Several other analysts have also recently weighed in on SRPT. Robert W. Baird lowered their price objective on shares of Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 4th. Weiss Ratings restated a “sell (d)” rating on shares of Sarepta Therapeutics in a research report on Monday, December 29th. Barclays cut their target price on Sarepta Therapeutics from $22.00 to $20.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 5th. Piper Sandler boosted their price objective on shares of Sarepta Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a report on Thursday, October 30th. Finally, BMO Capital Markets upgraded shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $50.00 target price on the stock in a research report on Monday, September 22nd. Nine investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and six have issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $33.76.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $21.31 on Wednesday. The stock has a market cap of $2.23 billion, a P/E ratio of -7.08, a PEG ratio of 0.50 and a beta of 0.48. The company has a quick ratio of 1.79, a current ratio of 2.95 and a debt-to-equity ratio of 0.78. The business’s 50-day moving average price is $20.71 and its two-hundred day moving average price is $19.65. Sarepta Therapeutics has a twelve month low of $10.41 and a twelve month high of $120.05.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.15). Sarepta Therapeutics had a negative return on equity of 4.85% and a negative net margin of 11.25%.The company had revenue of $399.36 million during the quarter, compared to the consensus estimate of $331.51 million. During the same quarter last year, the company posted $0.62 earnings per share. The firm’s revenue for the quarter was down 14.5% on a year-over-year basis. As a group, equities analysts predict that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Insider Buying and Selling at Sarepta Therapeutics

In other news, COO Ian Michael Estepan sold 13,187 shares of Sarepta Therapeutics stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $22.31, for a total transaction of $294,201.97. Following the completion of the transaction, the chief operating officer directly owned 193,300 shares in the company, valued at approximately $4,312,523. This trade represents a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in SRPT. AQR Capital Management LLC increased its holdings in shares of Sarepta Therapeutics by 214.2% during the first quarter. AQR Capital Management LLC now owns 5,385 shares of the biotechnology company’s stock valued at $344,000 after acquiring an additional 3,671 shares in the last quarter. Great Lakes Advisors LLC bought a new stake in Sarepta Therapeutics during the 1st quarter valued at about $224,000. Sovran Advisors LLC raised its holdings in Sarepta Therapeutics by 7.2% in the second quarter. Sovran Advisors LLC now owns 61,643 shares of the biotechnology company’s stock worth $1,054,000 after buying an additional 4,134 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Sarepta Therapeutics by 21.8% in the second quarter. Assenagon Asset Management S.A. now owns 867,939 shares of the biotechnology company’s stock worth $14,842,000 after buying an additional 155,358 shares in the last quarter. Finally, Public Employees Retirement System of Ohio grew its holdings in shares of Sarepta Therapeutics by 2.2% during the second quarter. Public Employees Retirement System of Ohio now owns 28,792 shares of the biotechnology company’s stock valued at $492,000 after buying an additional 607 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.